Ask AI
Pharmacist Excellence in RRMM

CE

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Pharmacists: 0.75 contact hour (0.075 CEUs)

Released: May 20, 2026

Expiration: November 19, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

BH has received 4 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. 
Based on her treatment history and patient-specific factors, which therapy would be best for her?

4.

What factors do you consider the most important when choosing a bispecific antibody for a patient with R/R MM? 

5.

An important part of therapy is counseling patients on expectations when they receive treatment with a bispecific antibody for R/R MM. 
During the pharmacy education visit, patient BH expresses concern about the risk of infection with linvoseltamab. What prophylaxis measures should be discussed with patient BH?

6.

Based on clinical trial data and real-world evidence, there are some key differences when comparing the drug linvoseltamab with other bispecific antibodies. 
A major difference of linvoseltamab includes which of the following?

7.

Which of the following toxicities is characteristic of GPRC5D-targeted agents compared with BCMA-targeted bispecific therapies?

8.

BH started initial treatment with linvoseltamab and began experiencing a fever of 101.4°F and generalized muscle aches. BH went to the emergency department, and they called you for guidance on the most appropriate management. What would you recommend as the appropriate guideline-based management for the cytokine release syndrome that BH is experiencing?